Botulism is a type of poisoning or infection caused by bacteria Clostridium botulinum. It is produced under low oxygen conditions and can have lethal effects on the human body. Some food sources such as preserved or fermented food and homemade canned food are potent breeding grounds for bacteria. Botulism directly affects nerve activity and blocks its functioning if left untreated for a longer period of time. Chest muscles, arms, and legs weakening are the most common problems of botulism. A person can be infected by consuming contaminated food that contains toxin or by injecting a toxin drug that causes wound botulism. The symptoms of botulism include double vision, drooping both eyelids, difficulty in swallowing, loss of facial expression, nausea, vomiting, and eventually constipation. Delay in treatment might result in paralysis, respiratory failure, or even death, as movement of muscles and respiration becomes difficult for the person affected with botulism.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the Botulism treatment market.
Top Impacting Factors
Increase in prevalence of communicable disease is expected to drive the growth of the market. In addition, rise in susceptibility of botulism among infants due to unhealthy eating habits and exposure to toxins acts as a key driver of the botulism treatment market. Moreover, rise in healthcare expenditure and rise in the standard of living which boosts the growth of the botulism treatment market.
In addition, increase in research & development for creating efficient and cost-effective treatments boost the growth of the botulism treatment market. Technological advancements in the healthcare industry have led to introduction of various types of antitoxins and antibiotics for the treatment of botulism, which notably contributes toward the growth of the market.
Furthermore, rise in awareness about health and government initiatives to improve healthcare infrastructure boost the market growth. In addition, increase in expenditure for creating other medical facilities propels the growth of the botulism treatment market
However, inadequate knowledge and lack of awareness about botulism may pose to be a key restraint of the market.
New Product Launches to Flourish the Market
In February 2021,Sihuan Pharmaceutical Holdings Group Ltd. got approval to launch the botulinum toxin product Letybo50U (Type A Botulinum Toxin for Injection).
In January 2021, Maypharm launched new botulinum toxin, METOX . It is an effective solution for smoothing any kind of wrinkles from moderate to severe, caused by daily active facial movements.
In January 2019, Huons Global launched a new botulinum toxin product Liztox. The company completed several clinical trials for the product and gained approval from the Ministry of Food and Drug Safety in the same year.
Surge in Usage of Botulism Treatment
Rise in prevalence of clostridium botulinum diseases boosts the need for botulism treatment. For instance, according to the Centers for Disease Control and Prevention, an average of 110 cases of botulism are reported annually in the US. About 25% of these cases are foodborne botulism. Approximately 70% of these cases are infant botulism. Hence, increase in number patients will lead to use treatment of botulism, which will further boost the market growth.
Key Benefits of the Report
- This study presents the analytical depiction of the Botulism treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Botulism Treatment Market Report
- Which are the leading players active in the Botulism treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is Botulism treatment market?
- What is Botulism treatment market prediction in the future?
- Who are the leading global players in the Botulism treatment market?
- What are the current trends and predicted trends?
- What are the key benefits of the Botulism treatment market report?
Botulism Treatment Market Report Highlights
By End User
Key Market Players
Merz Pharma, Allergan, Valeant Pharmaceuticals, XOMA, Lanzhou Insitie of Biological Products., Morphotek, Microbiotix, Medytox Solutions, Galderma